William Blair Reaffirms Their Buy Rating on Thermo Fisher (TMO)

William Blair analyst Matt Larew maintained a Buy rating on Thermo Fisher yesterday. The company’s shares closed yesterday at $546.76.

Valentine's Day Sale - 70% Off

• Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
• Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential

According to TipRanks, Larew is an analyst with an average return of -3.2% and a 43.82% success rate. Larew covers the Healthcare sector, focusing on stocks such as AptarGroup, Waters, and Twist Bioscience.

Currently, the analyst consensus on Thermo Fisher is a Strong Buy with an average price target of $677.73, representing a 23.95% upside. In a report released on February 2, J.P. Morgan also maintained a Buy rating on the stock with a $710.00 price target.

Based on Thermo Fisher’s latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $12.22 billion and a net profit of $1.98 billion. In comparison, last year the company earned a revenue of $11.4 billion and had a net profit of $1.83 billion

Based on the recent corporate insider activity of 74 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of TMO in relation to earlier this year. Most recently, in December 2025, Michel Lagarde, the EVP & COO of TMO sold 22,046.00 shares for a total of $12,424,243.76.